Richard A. Slayden

6.0k citations

85 papers · 4.7k indexed · h-index 37

Infectious Diseases top 0.5%
- Tuberculosis Research and Epidemiology 42
Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria 14
Epidemiology top 1%
- Mycobacterium research and diagnosis 23
- Pneumocystis jirovecii pneumonia detection and treatment 10
- Burkholderia infections and melioidosis 7
Organic Chemistry top 2%
Toxicology top 2%
Molecular Biology
- Cancer therapeutics and mechanisms 15
- Biochemical and Molecular Research 7
Genetics
- Bacterial Genetics and Biotechnology 7

Co-authors: Clifton E. Barry Richard Lee Peter J. Tonge Susan E. Knudson Gurdyal S. Besra Iwao Ojima Benjamin G. Schroeder Divya Awasthi
Cited by: Infectious Diseases Molecular Medicine Epidemiology
Journals: Science (1 paper)Proceedings of the National Academy of Sciences (1 paper)Journal of the American Chemical Society (1 paper)
Partner nations: United States Germany United Kingdom

In The Last Decade

Richard A. Slayden

82 papers receiving 4.6k citations

Peers

Countries citing papers authored by Richard A. Slayden

Since Specialization

Citations

This map shows the geographic impact of Richard A. Slayden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Slayden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Slayden more than expected).

Fields of papers citing papers by Richard A. Slayden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Slayden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Slayden. The network helps show where Richard A. Slayden may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard A. Slayden, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard A. Slayden Line = papers co-authored together Richard A. Slayden links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers ACS Infectious Diseases ·Mark J. Mitton‐Fry,Jason E. Cummings,Yanran Lu,Jillian F. Armenia,Jo Ann W. Byl,Alexandria A. Oviatt,Allison Bauman,Gregory T. Robertson,Neil Osheroff,Richard A. Slayden	2025	0
2	Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment Frontiers in Pharmacology ·Jason E. Cummings,Lisa K. Woolhiser,Vincent E. Guglielmi,Machenzie Wernsman,Adele Romano,Samantha Pauly,John T. Belisle,Nicholas D. Walter,Gregory T. Robertson,Richard A. Slayden	2025	0
3	A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection Frontiers in Immunology ·Savannah M. Rocha,Anna C. Fagre,Amanda S. Latham,Jason E. Cummings,Tawfik Aboellail,Philip Reigan,Devin A. Aldaz,Casey P. McDermott,Katriana A. Popichak,Rebekah C. Kading,Tony Schountz,Neil D. Theise,Richard A. Slayden,Ronald B. Tjalkens	2022	9
4	TPR1, a novel rifampicin derivative, demonstrates efficacy alone and in combination with doxycycline against the NIAID Category A priority pathogen Francisella tularensis JAC-Antimicrobial Resistance ·Jason E. Cummings,Keaton W. Slayden,Richard A. Slayden	2021	2
5	New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design International Journal of Molecular Sciences ·О. Б. Казакова,Roxana Racoviceanu,Anastasiya V. Petrova,Marius Mioc,Adrian Militaru,Lucreția Udrescu,Mihai Udrescu,Adrian Voicu,Jason E. Cummings,Gregory T. Robertson,Diane Ordway,Richard A. Slayden,Codruţa Şoica	2021	10
6	Immune Modulation as an Effective Adjunct Post-exposure Therapeutic for B. pseudomallei PLoS neglected tropical diseases ·William J. Wilson,Maryam F. Afzali,Jason E. Cummings,Marie E. Legare,Ronald B. Tjalkens,Chris Allen,Richard A. Slayden,William H. Hanneman	2016	17
7	Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection PLoS ONE ·Kun Wang,Stanley Langevin,Corey S. O’Hern,Mark D. Shattuck,Serenity Ogle,Adriana Forero,Juliet Morrison,Richard A. Slayden,Michael G. Katze,Michael Kirby	2016	15
8	Cell division inhibitors with efficacy equivalent to isoniazid in the acute murineMycobacterium tuberculosisinfection model Journal of Antimicrobial Chemotherapy ·Susan E. Knudson,Divya Awasthi,Kunal Kumar,Alexandra Carreau,Laurent Goullieux,Sophie Lagrange,Hélène Vermet,Iwao Ojima,Richard A. Slayden	2015	21
9	Adeno-associated virus gene therapy vector scAAVIGF-I for transduction of equine articular chondrocytes and RNA-seq analysis Osteoarthritis and Cartilage ·Daniel D. Hemphill,C. Wayne McIlwraith,Richard A. Slayden,R. Jude Samulski,Laurie R. Goodrich	2015	14
10	In vitro–in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis Tuberculosis ·Susan E. Knudson,Kunal Kumar,Divya Awasthi,Iwao Ojima,Richard A. Slayden	2014	25
11	Benzimidazole-based antibacterial agents against Francisella tularensis Bioorganic & Medicinal Chemistry ·Kunal Kumar,Divya Awasthi,Seung-Yub Lee,Jason E. Cummings,Susan E. Knudson,Richard A. Slayden,Iwao Ojima	2013	35
12	MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein BMC Microbiology ·Melissa V. Ramirez,Clinton C. Dawson,Rebecca Crew,Kathleen England,Richard A. Slayden	2013	19
13	Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei Journal of Antimicrobial Chemotherapy ·N. Liu,Jason E. Cummings,Kathleen England,Richard A. Slayden,Peter J. Tonge	2011	26
14	Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis Microbes and Infection ·Luke C. Kingry,Ryan M. Troyer,Nicole L. Marlenee,Helle Bielefeldt‐Ohmann,Richard A. Bowen,Alan R. Schenkel,Steven Dow,Richard A. Slayden	2010	13
15	Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis Journal of Antimicrobial Chemotherapy ·Richard A. Slayden,John T. Belisle	2008	27
16	Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery Tuberculosis ·Laurel Respicio,Pravin A. Nair,Qing Huang,Burcu Anil,Sylvia M. Tracz,J.J. Truglio,Caroline Kisker,Daniel P. Raleigh,Iwao Ojima,D. L. Knudson,Peter J. Tonge,Richard A. Slayden	2008	27
17	Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors Bioorganic & Medicinal Chemistry Letters ·Christopher W. am Ende,Susan E. Knudson,Nina Liu,James E. Childs,Todd J. Sullivan,Melissa E. Boyne,Hua Xu,Yelizaveta Gegina,D. L. Knudson,Francis Johnson,Charles A. Peloquin,Richard A. Slayden,Peter J. Tonge	2008	64
18	FtsZ: A Novel Target for Tuberculosis Drug Discovery Current Topics in Medicinal Chemistry ·Qing Huang,Peter J. Tonge,Richard A. Slayden,Teruo Kirikae,Iwao Ojima	2007	59
19	Disease State Differentiation and Identification of Tuberculosis Biomarkers via Native Antigen Array Profiling Molecular & Cellular Proteomics ·Mark J. Sartain,Richard A. Slayden,Krishna K. Singh,Suman Laal,John T. Belisle	2006	86
20	Mechanisms of isoniazid resistance in Mycobacterium tuberculosis Drug Resistance Updates ·Clifton E. Barry,Richard A. Slayden,Khisimuzi Mdluli	1998	22

About Richard A. Slayden

Richard A. Slayden is a scholar working on Molecular Medicine, Infectious Diseases and Epidemiology, having authored 85 papers that have together received 4.7k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (42 papers), Mycobacterium research and diagnosis (23 papers), Cancer therapeutics and mechanisms (15 papers), Antibiotic Resistance in Bacteria (14 papers), Pneumocystis jirovecii pneumonia detection and treatment (10 papers), Biochemical and Molecular Research (7 papers), Burkholderia infections and melioidosis (7 papers) and Bacterial Genetics and Biotechnology (7 papers). The work is most often cited by research in Infectious Diseases (2.4k citations), Molecular Medicine (599 citations) and Epidemiology (1.7k citations). Richard A. Slayden has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Clifton E. Barry, Richard Lee, Peter J. Tonge, Susan E. Knudson, Gurdyal S. Besra, Iwao Ojima, Benjamin G. Schroeder, Divya Awasthi, Kunal Kumar and Ying Yuan. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact